Levobunolol
Active ingredient: Levobunolol Hydrochloride
In short: Levobunolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
What is Levobunolol used for?
Levobunolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
âš Boxed warning (FDA's strongest warning)
As with other topically applied ophthalmic drugs, levobunolol hydrochloride ophthalmic solution may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents . Additionally, ophthalmic beta-blockers may impair compensatory tachycardia and increase risk of hypotension.
Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, levobunolol hydrochloride ophthalmic solution should be discontinued .
Levobunolol hydrochloride ophthalmic solution may potentiate syndromes associated with vascular insufficiency (i.e. Raynaud’s phenomenon), and therefore, should be used with caution in these patients. …
Levobunolol dosage
The recommended starting dose is one to two drops of levobunolol hydrochloride ophthalmic solution, 0.5% in the affected eye(s) once a day. In patients with more severe or uncontrolled glaucoma, levobunolol hydrochloride ophthalmic solution, 0.5% can be administered twice a day. As with any new medication, careful monitoring of patients is advised. Dosages above one drop of levobunolol hydrochloride ophthalmic solution, 0.5% twice a day are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with other ophthalmic IOP-lowering agents can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.
Warnings & precautions
Do not take this medicine if: Levobunolol hydrochloride ophthalmic solution is contraindicated in those individuals with bronchial asthma, or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease ; sinus bradycardia; second and third degree atrioventricular block; overt cardiac failure ; cardiogenic shock; or hypersensitivity to any component of these products.
Levobunolol hydrochloride ophthalmic solution, USP should be used with caution in patients with known hypersensitivity to other beta-adrenoceptor blocking agents.
Use with caution in patients with known diminished pulmonary function.
Levobunolol hydrochloride ophthalmic solution should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade or on intraocular pressure. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.
Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse rates, these medications must be used cautiously in patients with cerebrovascular insufficiency. Should signs or symptoms develop that suggest reduced cerebral blood flow while using levobunolol hydrochloride ophthalmic solution, alternative therapy should be considered.
In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires, in most cases, constricting the pupil with a miotic. Levobunolol hydrochloride ophthalmic solution has little or no effect on the pupil. When levobunolol hydrochloride ophthalmic solution is used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be followed with a miotic and not alone. …
Levobunolol side effects
In clinical trials the use of levobunolol hydrochloride ophthalmic solution has been associated with transient ocular burning and stinging in up to 1 in 3 patients, and with blepharoconjunctivitis in up to 1 in 20 patients. Decreases in heart rate and blood pressure have been reported .
The following adverse reactions have been reported rarely with the use of levobunolol hydrochloride ophthalmic solution: iridocyclitis, headache, transient ataxia, dizziness, lethargy, urticaria, and pruritus.
Decreased corneal sensitivity has been noted in a small number of patients. Although levobunolol has minimal membrane-stabilizing activity, there remains a possibility of decreased corneal sensitivity after prolonged use.
The following additional adverse reactions have been reported either with levobunolol hydrochloride ophthalmic solution or ophthalmic use of other beta-adrenergic receptor blocking agents:
BODY AS A WHOLE:Headache, asthenia, chest pain.
CARDIOVASCULAR:Bradycardia, arrhythmia, hypotension, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation, cardiac arrest.
DIGESTIVE:Nausea, diarrhea.
PSYCHIATRIC:Depression, confusion, increase in signs and symptoms of myasthenia gravis, paresthesia.
SKIN:Hypersensitivity, including localized and generalized rash, alopecia, Stevens-Johnson Syndrome. …
About this medicine
Levobunolol hydrochloride ophthalmic solution USP, 0.5% is a noncardioselective beta-adrenoceptor blocking agent for ophthalmic use.
Levobunolol hydrochloride is represented by the following structural formula:
Mol. Formula C
17H
25NO
3•HCl
Mol. Wt. 327.85
Chemical Name:(–)-5-[3-(
tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2
H)- naphthalenone hydrochloride.
Each mL of 0.5% contains:
Active:levobunolol hydrochloride 0.5%;
Inactives:polyvinyl alcohol 1.4%, sodium chloride, dibasic sodium phosphate, edetate disodium, sodium metabisulfite, monobasic potassium phosphate, and purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (5.5 - 7.5);
Preservative:benzalkonium chloride (0.004%).
How it works: Levobunolol hydrochloride is a noncardioselective beta-adrenoceptor blocking agent, equipotent at both beta 1and beta 2receptors. Levobunolol hydrochloride is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5ab1efbe-530b-4787-b40a-c7dbf18161e1. Read the full official label on DailyMed.
Related medicines
Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone